Traditional batch-based biologics manufacturing is limited by sequential processing, high infrastructure costs, and low productivity. Enzene’s Fully-Connected Continuous Manufacturing™ (FCCM™) platform — EnzeneX™, addresses these inefficiencies through a seamlessly integrated, end-to-end continuous process. Unlike other continuous manufacturing approaches that often operate in isolated segments, Enzene’s FCCM™ ensures uninterrupted connectivity from upstream to downstream, enabling true continuous flow. Now entering its next phase, EnzeneX™ 2.0 incorporates high-titer clones and advanced Process Analytical Technology (PAT) to achieve cost-efficient production at less than $40 per gram. With a proven track record and global client adoption, Enzene is expanding operations to the United States with a new FCCM-enabled facility in New Jersey, marking a major milestone in democratizing access to high-quality biologics. We are Enzene – pioneering the future of biomanufacturing.